Cancer research faces uncertain post-COVID landscapeThere’s a bright future ahead for cancer research in the UK, but only if the government is able Share XCancer research faces uncertain post-COVID landscapehttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/cancer-research-faces-uncertain-post-covid-landscape/
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a Share XNICE’s second Zytiga rejection ‘shows need for flexible pricing models’https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/
